AR expression in ER + ve/HER2-ve breast cancer was significantly associated with better breast cancer-specific survival (BCS), recurrence-free survival (RFS), and OS; however, AR expression became a poor prognostic factor in ER-ve patients [46]. This evidence concerns the gene ERBB2 and breast carcinoma.